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Continuous Infusion of Pantoprazole with Octreotide
Does Not Improve Management of Variceal Hemorrhage
Cesar Alaniz, Pharm.D., Rima A. Mohammad, Pharm.D., and Lynda S. Welage, Pharm.D.
Study Objective. To assess the effect of a prolonged continuous infusion of
pantoprazole on patient outcomes when the drug was combined with
standard octreotide therapy in patients with variceal hemorrhage.
Design. Retrospective cohort study.
Setting. Large academic hospital.
Patients. One hundred thirty adults who received treatment for a documented
variceal hemorrhage; 53 patients received standard octreotide therapy plus
a prolonged continuous infusion of pantoprazole (continuous-infusion
group) and 77 patients received either octreotide alone, octreotide with a
short-term (< 24 hrs) infusion of pantoprazole, or octreotide with
intermittent acid suppression (control group).
Measurements and Main Results. The primary outcome measure was the
number of units of packed red blood cells transfused during hospital-
ization. Baseline characteristics between the treatment groups were similar.
The duration of therapy for variceal hemorrhage was significantly longer in
the continuous-infusion group than in the control group. Transfusion
requirements for packed red blood cells (mean ± SD 6.4 ± 6.5 vs 5.8 ± 6.6
units, p=0.66) and platelets (8.8 ± 15.1 vs 5.1 ± 11.9 units, p=0.13) were
similar for the continuous-infusion group versus the control group. The
continuous-infusion group, however, received significantly more units of
fresh-frozen plasma than the control group (6.1 ± 10.6 vs 2.9 ± 6.2 units,
p=0.05). There was no significant difference in mortality rate between
groups.
Conclusion. Prolonged continuous infusions of pantoprazole with octreotide
seemed to offer no additional benefit compared with octreotide plus short-
term infusions of pantoprazole or intermittent acid suppression in the
management of acute variceal hemorrhage. Prospective studies should be
conducted to evaluate the role of continuously infused proton pump
inhibitors in this setting before their use can be advocated.
Key Words: pantoprazole, continuous infusion, varices, variceal hemorrhage,
octreotide.
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Variceal hemorrhage is a major, life-threatening
complication of gastroesophageal varices, which
develop in approximately 50% of patients with
cirrhosis.1 The frequency of variceal rupture
varies depending on the size of the varices, but is
generally 5–15%/year. Despite improvements in
treatment over the last decade, variceal hemorrhage
is associated with a mortality rate of at least 20%
after 6 weeks.2, 3
Recommendations for controlling active bleeding
include starting pharmacologic therapy with
somatostatin, its analogs, or terlipressin and
continuing therapy for 3–5 days.1 Octreotide is
the somatostatin analog available in the United
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States. When given as a continuous infusion, the
agent has been associated with improved
outcomes.4 Octreotide decreases portal pressure
by inducing splanchnic vasoconstriction, leading
to control of bleeding.
Continuous infusions of proton pump inhibitors
have been associated with a decreased risk for
recurrent bleeding and a decreased need for
endoscopic intervention in patients with bleeding
peptic ulcers.5, 6 Data support the use of omepra-
zole administered as an 80-mg bolus followed by
a continuous infusion of 8 mg/hour for 72 hours
to prevent recurrent ulcerous bleeding in high-
risk patients. Although parenteral omeprazole is
not available in the United States, parenteral
pantoprazole has been recommended for use.7
Although data support the continuous infusion of
a proton pump inhibitor in the setting of
nonvariceal hemorrhage, to our knowledge, no
research has been conducted to evaluate its use in
patients with variceal hemorrhage. Thus, we
investigated the potential benefit of administering
pantoprazole as a prolonged continuous infusion
combined with standard octreotide therapy
compared with octreotide alone or octreotide with
intermittent acid suppression or with short-term
(< 24 hrs) continuous-infusion pantoprazole to
manage bleeding varices.
Methods
This retrospective cohort study was conducted
at a major academic medical center (University of
Michigan Medical Center, Ann Arbor, MI). The
study was approved by the University of
Michigan’s institutional review board. Patient
consent was not required due to the noninter-
ventional, retrospective nature of the study.
We reviewed the hospital’s patient database to
identify patients who had received continuous
infusions of octreotide between January 2002 and
June 2005. All patients who had a documented
variceal hemorrhage, as determined by esophago-
gastroduodenoscopy, were included. The null
hypothesis was that continuous infusions of
pantoprazole therapy for longer than 24 hours
reduced variceal bleeding. Therefore, we assigned
patients to one of two groups: a continuous-
infusion group and a control group. The
continuous-infusion group consisted of patients
who had received continuously infused panto-
prazole for at least 24 hours in addition to
standard octreotide therapy. The control group
was composed of patients who had received
either octreotide alone, octreotide with panto-
prazole that was continuously infused for less
than 24 hours, or octreotide with intermittent
acid suppression. Because the source of hemor-
rhage is not known at presentation, we allowed
patients in the control group to have received
empiric infusions of pantoprazole, a practice that
consensus guidelines support.7
Demographic data were collected, including
age, race-ethnicity, sex, Child-Pugh score, and
Acute Physiology and Chronic Health Evaluation
(APACHE) III scores, if available. Relevant
medical histories were documented and included
a history of transjugular intrahepatic portosystemic
shunt procedures, number of variceal bleeding
episodes, previous use of -blockers, and
duration of cirrhosis. Laboratory data were
collected at baseline and end of therapy,
including hemoglobin level and hematocrit;
albumin, bilirubin, blood urea nitrogen, and
serum creatinine concentrations; and activated
partial thromboplastin times (aPTTs) and
international normalized ratios (INRs). Dosages
and durations of pantoprazole given as both
intermittent injections and continuous infusions
and octreotide given as continuous infusions
were recorded. Other acid-suppressive therapy
was also recorded.
The primary outcome measure was the number
of units of packed red blood cells transfused
during the patient’s hospitalization. Secondary
outcome measures included the number of units
of fresh frozen plasma, platelets, and cryopre-
cipitate transfused; endoscopic interventions;
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frequency of rebleeding; length of stay in the
intensive care unit; length of hospitalization; and
mortality rate. Episodes of rebleeding were based
on repeated use of blood transfusions after initial
stabilization, repeated endoscopy, or repeated
transjugular intrahepatic portosystemic shunting.
Statistical Analysis
To prove the null hypothesis, the continuous-
infusion group and the control group were
compared for baseline characteristics, duration of
drug infusions, endoscopic interventions and
clinical outcomes, and number of transfusions
received. The Student t test was used to compare
continuous variables, and the Fisher exact test or
2 test was used to compare categoric data. A p
value of 0.05 or less was considered to indicate a
statistically significant difference.
Results
Demographic and Treatment Data
Of 336 patients screened, 130 met the criteria
for inclusion. The 206 patients excluded had
received octreotide for reasons other than variceal
bleeding (180 patients), or they had an incom-
plete inpatient record (26 patients). Of the 130
patients in the study, 53 were in the continuous-
infusion group. Of the 77 in the control group,
three received octreotide alone, 24 were given
octreotide with a short-term infusion of panto-
prazole, and 50 received octreotide with inter-
mittent acid suppression. Acid suppressive
therapy consisted of intravenous pantoprazole
twice/day in 48 patients and intravenous
ranitidine 3 times/day in two patients.
Baseline characteristics were similar between
treatment groups (Table 1). More patients in the
control group than in the continuous-infusion
group had a history of variceal bleeding (57% vs
43%, p=0.086) and previous -blocker therapy
(45% vs 30%, p=0.058). In addition, mean ± SD
albumin levels tended to be higher (2.4 ± 0.7 vs
2.2 ± 0.7 g/dl, p=0.07) and bilirubin levels tended
to be lower (3.4 ± 5.7 vs 5.0 ± 7.1 mg/dl, p=0.15)
in the control group than in the continuous-
infusion group. Measures of coagulopathy (INR
and aPTT) were similar between groups, as were
mean ± SD Child-Pugh scores (control 9.4 ± 2.1
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Table 1. Baseline Characteristics
Continuous- Control
Infusion Groupa Groupb
Characteristic (n=53) (n=77) p Value
No. (%) of Patients
Caucasian 43 (81) 56 (73) NR
Male 37 (70) 53 (69) 0.94
Previous variceal bleeding 23 (43) 44 (57) 0.086
Previous -blocker therapy 16 (30) 35 (45) 0.058
Gastric varices 16 (30) 21 (27) 0.84
Mean ± SD
Age (yrs) 52.0 ± 11.2 52.1 ± 11.8 0.99
Albumin level (g/dl) 2.2 ± 0.7 2.4 ± 0.7 0.07
Bilirubin level (mg/dl) 5.0 ± 7.1 3.4 ± 5.7 0.15
aPTT (sec) 37.3 ± 15.2 33.5 ± 11.1 0.10
INR 1.6 ± 0.6 1.5 ± 0.6 0.31
Hemoglobin level (g/dl) 9.1 ± 2.2 9.1 ± 2.5 0.96
Hematocrit (%) 27.3 ± 6.2 27.0 ± 6.9 0.83
Child-Pugh score 9.9 ± 2.4 9.4 ± 2.1 0.21
APACHE III scorec 83.8 ± 21.7 85.2 ± 39.3 0.85
Duration of infusion (hrs)
Octreotide 70.9 ± 33.2 48.4 ± 31.9 0.0001
Pantoprazole 63.3 ± 48.9 3.5 ± 6.8 <0.001
NR = not reported; aPTT = activated partial thromboplastin time; INR = international
normalized ratio; APACHE = Acute Physiology and Chronic Health Evaluation.
aPatients received standard octreotide therapy plus a prolonged continuous infusion of
pantoprazole.
bPatients received either octreotide alone, octreotide with a short-term (< 24 hrs) infusion
of pantoprazole, or octreotide with intermittent acid suppression.
cData were available for 32 patients in the continuous-infusion group and 40 patients in the
control group.
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vs continuous infusion 9.9 ± 2.4, p=0.21) and
APACHE III scores (control 85.2 ± 39.3 vs
continuous infusion 83.8 ± 21.7, p=0.85).
Octreotide was infused for a mean ± SD of 48.4
± 31.9 hours (range 1.5–173 hrs) in the control
group compared with 70.9 ± 33.2 hours (range
8–149 hrs) in the continuous-infusion group
(p=0.0001). Doses of octreotide were 47.1 ± 11.9
and 46.0 ± 9.1 µg/hour in the control and
continuous-infusion groups, respectively (p=0.6).
Pantoprazole was infused for 3.5 ± 6.8 hours
(range 0–22 hrs) in the control group compared
with 63.3 ± 48.9 hours (range 25–332 hrs) for
continuous infusion (p<0.001). The dosage of
pantoprazole used for continuous infusion was 8
mg/hour for 52 of 53 patients in the continuous-
infusion group and for 22 of 24 patients in the
control group.
Seventy-two (94%) patients in the control
group received a proton pump inhibitor (as a
continuous infusion for < 24 hrs and/or inter-
mittent injections). Fifty patients (94%) in the
continuous-infusion group received intermittent
therapy with a proton pump inhibitor after their
continuous infusions of pantoprazole were
discontinued.
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Table 2. Study Interventions and Outcomes
Continuous- Control
Infusion Groupa Groupb
Variable (n=53) (n=77) p Valuec
Transfusions (units)
Day 1
Packed red blood cells
Mean ± SD 3.0 ± 3.0 2.9 ± 3.2 0.85
Median 2 2
Fresh-frozen plasma
Mean ± SD 1.7 ± 2.6 1.0 ± 1.8 0.07
Median 0 0
Platelets
Mean ± SD 2.1 ± 3.7 1.3 ± 3.9 0.24
Median 0 0
Throughout hospital stay
Packed red blood cells
Mean ± SD 6.4 ± 6.5 5.8 ± 6.6 0.66
Median 4 4
Fresh-frozen plasma
Mean ± SD 6.1 ± 10.6 2.9 ± 6.2 0.05
Median 2 0.5
Platelets
Mean ± SD 8.8 ± 15.1 5.1 ± 11.9 0.13
Median 0 0
Laboratory value at
end of therapy, mean ± SD
Hemoglobin level (g/dl) 10.7 ± 1.5 10.7 ± 1.5 0.9
Hematocrit (%) 30.7 ± 4.6 31.1 ± 4.8 0.65
Clinical outcomes,
no. (%) of patients
Recurrent variceal bleed 7 (13) 4 (5) 0.12
Mortality 7 (13) 13 (17) 0.63
Endoscopic interventions,
no. (%) of patients
Banding 22 (42) 31 (40) 0.89
Sclerotherapy 19 (36) 23 (30) 0.47
TIPS 18 (34) 24 (31) 0.74
TIPS = transjugular intrahepatic portosystemic shunting.
aPatients received standard octreotide therapy plus a prolonged continuous infusion of
pantoprazole.
bPatients received either octreotide alone, octreotide with a short-term (< 24 hrs) infusion of
pantoprazole, or octreotide with intermittent acid suppression.
cStudent t test was used to compare all variables all except clinical outcomes and endoscopic
interventions, for which the 2 test was used.
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Outcome Measures
Mean numbers of packed red blood cell and
platelet transfusions on day 1 of variceal
hemorrhage and throughout hospitalization were
similar between the study groups (Table 2).
During hospitalization for the control and
continuous-infusion groups, total mean ± SD
packed red blood cells transfused were 5.8 ± 6.6
and 6.4 ± 6.5 units, respectively (p=0.66), and
total platelet transfusions were 5.1 ± 11.9 and 8.8
± 15.1 units, respectively (p=0.13). Patients
given continuous infusions received more fresh
frozen plasma than did control patients (total 6.1
± 10.6 vs 2.9 ± 6.2 units, p=0.05).
At the end of therapy, the control and
continuous-infusion groups had similar mean ±
SD serum hemoglobin concentrations (10.7 ± 1.5
vs 10.7 ± 1.5 g/dl, p=0.9) and hematocrits (31.1 ±
4.8% vs 30.7 ± 4.6%, p=0.65; Table 2). Four
(5%) control patients had a recurrence of variceal
hemorrhage compared with seven (13%) in the
continuous-infusion group (p=0.12). We found
no significant difference between the groups with
respect to variceal banding, sclerotherapy, or
transjugular intrahepatic portosystemic shunt
placement. Mortality rates were similar, with 13
(17%) deaths in the control group and seven
(13%) deaths in the continuous-infusion group,
p=0.63.
Subgroup Analyses
Of 53 patients who received a continuous
infusion of pantoprazole for at least 24 hours, 16
received therapy for more than 72 hours (mean ±
SD 108.7 ± 64.3 hrs). Also, the octreotide
infusion was significantly longer in this subgroup
than in the control group (92.4 ± 32.7 vs 48.4 ±
31.9 hrs, p<0.001). At baseline, for this
subgroup, serum hemoglobin levels, aPTTs, and
INRs did not significantly differ from the control
group. Also similar between this subgroup and
the control group were the mean ± SD number of
packed red blood cells transfused on day 1 (2.5 ±
1.9 vs 3.0 ± 3.4 units, p=0.64) and the total
number of packed red blood cells transfused (5.9
± 6.9 vs 5.8 ± 6.8 units, p=0.96).
Sixteen patients in the continuous-infusion
group and 21 control patients presented with
bleeding from gastric varices. Evaluation of these
patients showed no significant difference in units
of packed red blood cells transfused (continuous
infusion 6.0 units vs control 4.8 units, p=0.48).
Pantoprazole infusions were significantly longer
in this continuous-infusion group (mean ± SD
63.3 ± 30.7 hrs) than in this control group (3.7 ±
7.3 hrs, p<0.001). Overall, octreotide infusions
were longer for these 16 patients receiving
continuous infusions (72.0 ± 31.6 hrs) than for
the 21 control patients (46.6 ± 41.8 hrs, p=0.04).
Discussion
The estimated overall incidence of acute upper
gastrointestinal bleeding is 50–100 episodes/
100,000 person-years, with an annual hospital-
ization rate of 100/100,000 hospital admissions.8
The most common cause of such hemorrhage is
ulcerative disease. National surveys have shown
that approximately 10% of patients with upper
gastrointestinal bleeding present with variceal
hemorrhage,9, 10 but this rate may be as high as
30% in large urban areas.11 The general
recommendation is to start therapy with a proton
pump inhibitor in patients who are being
evaluated for upper gastrointestinal bleeding.7
In our study, to account for the intent of
pantoprazole use, we assigned all patients who
had pantoprazole continuously infused for less
than 24 hours to the control group. The
assumption was that these patients might have
received empiric therapy before undergoing
esophagogastroduodenoscopy and that their
infusions were stopped when variceal bleeding
was diagnosed. About 69% of patients in this
group did not receive continuously infused
pantoprazole. Although the mean duration of
pantoprazole infusion in the continuous-infusion
group was not 72 hours, as it is prescribed for
nonvariceal bleeding, it was significantly longer
than the mean duration in the control group.
Despite the prolonged infusion of pantoprazole,
we observed no added benefit with respect to
transfusion requirements. The mean number of
transfusions for both the continuous-infusion
group (6.4 units) and the control group (5.8
units) was somewhat higher than those reported
in previous prospective studies.4, 12, 13 Two
aspects of our patient population may account
for the difference. First, our patients’ mean
hemoglobin concentration after therapy (10.7
g/dl in both groups) was higher than hemoglobin
goals in previous studies (9 g/dl,4 8 g/dl,13 and > 7
g/dl12). Second, Child-Pugh class C disease was
more prevalent in our patients (44.6%) than in
patients from previous studies (36.7%,4 14.8%13
and 11.8%12).
Despite recommendations that octreotide
infusions should last 3–5 days,1 the mean
duration of therapy in our control group was
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48.4 hours compared with 70.9 hours in the
continuous-infusion group. It is difficult to
account for this discrepancy, as baseline
characteristics, endoscopic interventions, and
responses to therapy suggested that the treatment
groups were similar. Continuous infusion of
pantoprazole in the setting of upper gastro-
intestinal bleeding is a relatively recent practice, a
fact reflected in the patient groups. That is, most
of the patients treated last were in the continuous-
infusion group. Thus, the prolonged adminis-
tration of octreotide in the continuous-infusion
group may have simply reflected an evolution in
practice. Although it may be argued that this
difference provided an additional benefit to the
continuous-infusion group, significant controversy
surrounds both the relative efficacy of octreotide
and the time frame in which it exerts its effect.
A review of existing data suggested that the net
benefit of octreotide is that it saves 0.5 unit of
blood/patient.14 In addition, desensitization15 to
the effects of octreotide in patients with portal
hypertension implies a limited duration of
efficacy,16 an observation made previously.4
Therefore, although our two treatment groups
received octreotide for different durations, we do
not believe that this difference affected patient
outcomes.
The use of a proton pump inhibitor in the
setting of a bleeding peptic ulcer after endoscopic
intervention has been shown to decrease the
number of blood transfusions and the frequency
of rebleeding in high-risk patients.5 The
presumed mechanism is maintenance of the
gastric pH above 6 to optimize platelet aggregation
and subsequent clot formation.17, 18
Our study did not demonstrate a beneficial
effect of continuously infused pantoprazole on
either the requirements for blood transfusion or
the frequency of rebleeding. Also, our subset
analysis of patients who received continuous
infusions of pantoprazole for at least 72 hours
revealed no benefit in outcomes measures. Most
bleeding episodes were due to esophageal varices
rather than gastric varices. Therefore, the potential
gain of achieving clinically significant acid
suppression in this patient population with
esophageal varices seems unlikely. Because
proton pump inhibitors have demonstrated
improvements in actively bleeding peptic ulcers,
patients presenting with bleeding gastric varices
may benefit from continuously infused
pantoprazole. Subset analyses of patients
presenting with gastric variceal hemorrhage did
not reveal any advantage with infusions of
pantoprazole.
The retrospective nature of this study was one
of its limitations. Furthermore, the duration of
infusions varied widely within the treatment
groups, though the mean durations did differ
significantly. Although the APACHE III scores
that were available were similar between the
groups, the continuous-infusion group received
more fresh-frozen plasma, they received longer
infusions of octreotide, and they tended to have
more recurrent bleeding than the control group.
These differences suggested that the groups
might not have been equal at baseline. It is also
possible that intensified therapy may have been
related to changes in practice over time.
Conclusion
The findings of our study did not reveal any
benefit of prolonged continuous infusions of
pantoprazole compared with short-term (< 24
hrs) infusions or intermittent dosing when it was
combined with octreotide in the management of
variceal hemorrhage. Prospective studies should
be conducted to evaluate the role of continuously
infused proton pump inhibitors in this setting
before their use can be advocated.
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